Volume | 2 |
|
|||||
News | - | ||||||
Day High | Low High |
||||||
Day Low |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Ligand Pharmaceuticals Incorporated | LGND | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
72.52 |
Trades | Volume | Avg Volume | 52 Week Range |
---|---|---|---|
2 | 2 | - | 49.24 - 94.57 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
08:00:06 | 1 | $ 74.00 | USD |
Ligand Pharmaceuticals Incorporated Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
1.28B | 17.71M | - | 131.31M | 52.15M | 2.95 | 24.62 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Ligand Pharmaceuticals News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical LGND Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 81.48 | 81.73 | 72.50 | 78.76 | 162,116 | -8.96 | -11.00% |
1 Month | 72.91 | 81.73 | 68.245 | 76.71 | 150,685 | -0.39 | -0.53% |
3 Months | 75.55 | 94.57 | 68.245 | 76.21 | 173,871 | -3.03 | -4.01% |
6 Months | 53.80 | 94.57 | 49.24 | 70.67 | 140,588 | 18.72 | 34.80% |
1 Year | 75.63 | 94.57 | 49.24 | 69.98 | 119,585 | -3.11 | -4.11% |
3 Years | 148.67 | 169.98 | 49.24 | 95.70 | 144,453 | -76.15 | -51.22% |
5 Years | 126.00 | 219.75 | 49.24 | 106.02 | 240,677 | -53.48 | -42.44% |
Ligand Pharmaceuticals Description
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material. |